BioSpace News Archive

Vireo Health International, Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), the leading physician-led, science-focused multi-state cannabis company, today reported financial results for its first quarter ended March 31, 2021.

REGENXBIO Inc. (Nasdaq: RGNX) today announced a safety update and additional positive interim data from the ongoing Phase I/II trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome

OTO-825 administration rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency

Biogen Inc. (Nasdaq: BIIB) today announced topline results from the Phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP).

Solid Biosciences Inc. (Nasdaq: SLDB), today provided a first quarter 2021 business update, which includes updates on two additional patients dosed in the IGNITE DMD clinical trial, long term biopsy data from prior patients dosed in the high dose 2E14 vg/kg cohort of the trial, advancement of a next-generation gene therapy program for Duchenne and financial results for the quarter ended March 31, 2021

TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the first quarter ended March 31, 2021 and provided a business update.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal second quarter ended March 31, 2021.

Aveanna Healthcare Holdings Inc. (“Aveanna”) today announced that the company will release its first quarter results after the market close on Tuesday, May 25, 2021, to be followed by a conference call on Wednesday, May 26, 2021 at 10:00 a.m. (Eastern Time).

Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced financial results for the three months ended March 31, 2021, and provided an update on clinical development programs with GEN-1, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase I/II clinical development for the localized treatment of ovarian cancer, and ThermoDox

Viridian Therapeutics, Inc. announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will present a company overview at the virtual Oppenheimer Rare & Orphan Disease Summit and participate in a fireside chat at the Jefferies Virtual Healthcare Conference.